Showing results (81-90 of 344) with videos related to
Sort By:
Pageof 35
Internal and Emergency Medicine|September 21, 2018
Metabolic and vascular effects of silybin in hypertensive patients with high 1-h post-load plasma glucoseAngela Sciacqua, Maria Perticone, Giovanni Tripepi, et al.International Journal of Cardiology|February 17, 2012
Creatinine and insulin predict cardiac mass in drug-naïve hypertensive patientsSofia Miceli, Raffaele Maio, Maria Perticone, et al.Cardiovascular Diabetology|January 13, 2024
Sex differences in the association between insulin resistance and non-fatal myocardial infarction across glycaemic statesAlessia Riccio, Elena Fortin, Linda Mellbin, et al.Oncotarget|September 9, 2017
Insulin-like growth factor-1 is a negative modulator of glucagon secretionElettra Mancuso, Gaia C Mannino, Concetta Di Fatta, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 22, 2008
Kidney function and risk factors for left ventricular hypertrophy in untreated uncomplicated essential hypertensionFrancesco Perticone, Raffaele Maio, Carmen Ruberto, et al.Diabetes Care|April 26, 2011
One-hour postload plasma glucose levels and left ventricular mass in hypertensive patientsAngela Sciacqua, Sofia Miceli, Giuseppe Carullo, et al.Diabetes|October 12, 2007
Endothelial dysfunction and C-reactive protein are risk factors for diabetes in essential hypertensionFrancesco Perticone, Raffele Maio, Angela Sciacqua, et al.Journal of Internal Medicine|October 5, 2023
Association between higher duodenal levels of the fructose carrier glucose transporter-5 and nonalcoholic fatty liver disease and liver fibrosisFrancesca De Vito, Evelina Suraci, Raffaella Marasco, et al.Diabetes Research and Clinical Practice|August 2, 2022
Sex-specific differences in prevalence of nonalcoholic fatty liver disease in subjects with prediabetes and type 2 diabetesElena Succurro, Maria Adelaide Marini, Teresa Vanessa Fiorentino, et al.Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 29, 2012
Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%Allen B King, Eduard Montanya, Richard E Pratley, et al.Pageof 35